Portal
Cambridge, Massachusetts, United States · Artificial Intelligence, Biotechnology · 77 employees
Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. We are implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and AI-driven technologies. Portal’s initial product suite is based on a proprietary
Funding history
- Venture - Series Unknown — $9.0M — May 2026
- Venture - Series Unknown — $11.7M — May 2026
- Venture - Series Unknown — $11.7M — Dec 2024
- Seed — $7.0M — Dec 2024
- Seed — $5.0M — Mar 2024
Recent signals
- Jun 19, 2026: Portal Biotechnologies Secures $9M Financing Round Led by NFX to Enhance Drug Discovery and Cell Therapy Manufacturing.
- May 29, 2026: Raised $9.0M in Venture - Series Unknown
- May 29, 2026: Raised $11.7M in Venture - Series Unknown
- Jun 24, 2025: Portal Biotechnologies Secures $8M DARPA Contract for Portable Cell Therapy Device Development.
- Dec 26, 2024: Raised $11.7M in Venture - Series Unknown
- Dec 19, 2024: Raised $7.0M in Seed
- Dec 19, 2024: Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round
- Mar 19, 2024: Raised $5.0M in Seed
See plans & pricing → Track Portal’s funding, hiring, and signals — with verified contacts — on Fundz.